文献速递口腔黏膜病

基于网络药理学、机器学习与分子对接探究吡美莫司治疗口腔扁平苔藓的靶点与机制

[Exploring the therapeutic targets and molecular mechanisms of pimecrolimus in the treatment of oral lichen planus based on network pharmacology, machine learning, and molecular docking].
PubMed 文献 · Zhonghua Kou Qiang Yi Xue Za Zhi · 2026-01-01

本研究采用网络药理学、机器学习和分子对接方法,系统探究吡美莫司治疗口腔扁平苔藓(OLP)的潜在靶点与机制。共筛选出20个交集靶点,主要富集于PI3K-Akt、TNF和NF-κB等炎症通路;识别出MMP2、MTOR和ERBB2等关键靶点,其在糜烂型与非糜烂型OLP中表达差异显著;分子对接显示吡美莫司与上述靶点结合能均低于-5 kcal/mol。

要点

  • 吡美莫司可能通过调控MMP2、MTOR和ERBB2等关键靶点干预OLP进展。
  • MMP2和MTOR在糜烂型OLP中表达显著高于非糜烂型,ERBB2则相反。
  • 吡美莫司与核心靶点结合能均低于-5 kcal/mol,提示良好结合活性。

核心结论

  • 吡美莫司可能通过协同调控MMP2(作用于糜烂型OLP)、MTOR(作用于糜烂型OLP)及ERBB2(作用于非糜烂型OLP)等关键靶点,抑制PI3K-Akt、TNF和NF-κB等炎症通路活性,从而干预OLP进展。

研究设计与样本

  • 研究通过SwissTargetPrediction、比较毒理基因组学数据库及GeneCards数据库获取吡美莫司与OLP相关靶点,筛选交集基因后进行富集分析、PPI网络构建、机器学习评估及分子对接验证。

主要发现

  • 共筛选出20个交集靶点,主要富集于PI3K-Akt、TNF、NF-κB等炎症相关通路。
  • PPI与机器学习识别出MMP2、MTOR、ERBB2等关键靶点。
  • MMP2与MTOR在糜烂型OLP中的表达(分别为6.67、3.54)均显著高于非糜烂型OLP(分别为4.39、3.27)(P<0.001,P=0.012)。
  • ERBB2在非糜烂型OLP中的表达(5.55)显著高于糜烂型OLP(4.86)(P=0.001)。
  • 分子对接显示吡美莫司与上述靶点结合能均低于-5 kcal/mol。

关键数值与推荐

  • MMP2在糜烂型OLP中表达为6.67,非糜烂型为4.39(P<0.001)。
  • MTOR在糜烂型OLP中表达为3.54,非糜烂型为3.27(P=0.012)。
  • ERBB2在非糜烂型OLP中表达为5.55,糜烂型为4.86(P=0.001)。
  • 吡美莫司与核心靶点结合能均低于-5 kcal/mol。

临床怎么用

  • 提示吡美莫司可能作为OLP的潜在治疗药物,尤其需结合糜烂型与非糜烂型OLP的靶点表达差异进行个体化考量。
  • MMP2、MTOR和ERBB2可能作为OLP分型相关的候选生物标志物或治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To systematically investigate the potential targets and therapeutic mechanisms of pimecrolimus in the treatment of oral lichen planus (OLP) using network pharmacology, machine learning, and molecular docking approaches. Methods: Pimecrolimus and OLP-related targets were retrieved from SwissTargetPrediction, Comparative Toxicogenomics Database, and GeneCards database. Intersecting genes underwent gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. A protein-protein interaction (PPI) network was constructed, with eXtreme Gradient Boosting algorithm and SHapley Additive exPlanations employed to evaluate target importance. Molecular docking validated binding affinity between pimecrolimus and core targets. Results: Twenty intersecting targets were identified, primarily enriched in inflammatory pathways, including phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway, tumor necrosis factor (TNF) signaling pathway, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. PPI and machine learning identified key targets including matrix metalloproteinase 2 (MMP2), mechanistic target of rapamycin (MTOR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). The expression levels of MMP2 and MTOR in erosive OLP (6.67 and 3.54, respectively) were significantly higher than those in non-erosive OLP (4.39 and 3.27, respectively) (P<0.001 and P=0.012). In contrast, the expression level of ERBB2 in non-erosive OLP (5.55) was significantly higher than that in erosive OLP (4.86) (P=0.001). Molecular docking demonstrated that pimecrolimus had good binding activity with all the above targets, with binding energies all lower than -5 kcal/mol. Conclusions: This study systematically demonstrates that pimecrolimus may interfere with OLP progression by synergistically regulating key targets such as MMP2 (acting on erosive OLP), MTOR (acting on erosive OLP), and ERBB2 (acting on non-erosive OLP), and inhibiting the activity of inflammatory pathways including PI3K-Akt, TNF, and NF-κB. 目的: 基于网络药理学、机器学习与分子对接方法,系统探究吡美莫司治疗口腔扁平苔藓(OLP)的潜在靶点及作用机制。 方法: 通过SwissTargetPrediction、比较毒理基因组学数据库及GeneCards等数据库获取吡美莫司与OLP的相关靶点,筛选交集基因后进行基因本体论和京都基因与基因组数据库通路富集分析;构建蛋白质-蛋白质相互作用(PPI)网络,结合极端梯度提升算法与沙普利加法解释评估靶点重要性,并采用分子对接验证吡美莫司与核心靶点的结合能力。 结果: 共筛选出20个交集靶点,主要富集于磷脂酰肌醇3激酶(PI3K)-蛋白激酶B(Akt)、肿瘤坏死因子(TNF)、核因子κB(NF-κB)等炎症相关通路。PPI与机器学习识别出基质金属蛋白酶2(MMP2)、哺乳动物雷帕霉素靶蛋白(MTOR)、Erb-B2受体酪氨酸激酶2(ERBB2)等关键靶点,其中MMP2与MTOR在糜烂型OLP中的表达(分别为6.67、3.54)均显著高于二者在非糜烂型OLP中的表达(分别为4.39、3.27)(P<0.001,P=0.012),ERBB2在非糜烂型OLP中的表达(5.55)显著高于其在糜烂型OLP中的表达(4.86)(P=0.001)。分子对接显示吡美莫司与上述靶点均具有良好的结合活性,结合能均低于-5 kcal/mol。 结论: 本研究系统阐明吡美莫司可能通过协同调控MMP2(作用于糜烂型OLP)、MTOR(作用于糜烂型OLP)及ERBB2(作用于非糜烂型OLP)等关键靶点,抑制PI3K-Akt、TNF和NF-κB等炎症通路活性,从而干预OLP的进展。.

来源:Zhonghua Kou Qiang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shang QH, Jila P, Yilihamu A, et al. [Exploring the therapeutic targets and molecular mechanisms of pimecrolimus in the treatment of oral lichen planus based on network pharmacology, machine learning, and molecular docking]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2026. PMID: 41786520. doi:10.3760/cma.j.cn112144-20251126-00464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。